Cerus Co. (NASDAQ:CERS) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund cut its position in Cerus Co. (NASDAQ:CERS) by 14.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 115,400 shares of the biotechnology company’s stock after selling 18,800 shares during the period. New York State Common Retirement Fund owned 0.09% of Cerus worth $585,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of CERS. BlackRock Inc. grew its stake in Cerus by 2.5% in the 3rd quarter. BlackRock Inc. now owns 10,670,764 shares of the biotechnology company’s stock valued at $76,936,000 after buying an additional 264,767 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Cerus by 2.4% during the 3rd quarter. Vanguard Group Inc. now owns 6,626,832 shares of the biotechnology company’s stock valued at $47,779,000 after purchasing an additional 154,112 shares in the last quarter. Vanguard Group Inc grew its position in shares of Cerus by 2.4% during the 3rd quarter. Vanguard Group Inc now owns 6,626,832 shares of the biotechnology company’s stock valued at $47,779,000 after purchasing an additional 154,112 shares in the last quarter. Peregrine Capital Management LLC grew its position in shares of Cerus by 28.4% during the 4th quarter. Peregrine Capital Management LLC now owns 2,143,325 shares of the biotechnology company’s stock valued at $10,867,000 after purchasing an additional 474,106 shares in the last quarter. Finally, Man Group plc grew its position in shares of Cerus by 116.2% during the 3rd quarter. Man Group plc now owns 1,043,123 shares of the biotechnology company’s stock valued at $7,521,000 after purchasing an additional 560,723 shares in the last quarter. Institutional investors own 66.23% of the company’s stock.

In other news, CFO Kevin Dennis Green sold 23,524 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $2.05, for a total transaction of $48,224.20. Following the completion of the transaction, the chief financial officer now directly owns 66,825 shares of the company’s stock, valued at $136,991.25. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO William Mariner Greenman sold 7,781 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $6.48, for a total transaction of $50,420.88. The disclosure for this sale can be found here. Insiders sold 57,650 shares of company stock valued at $257,460 over the last three months. 6.80% of the stock is currently owned by insiders.

Shares of NASDAQ:CERS opened at $6.04 on Friday. The company has a quick ratio of 2.53, a current ratio of 2.79 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $827.20 million, a P/E ratio of -13.73 and a beta of 1.42. Cerus Co. has a 52-week low of $4.70 and a 52-week high of $8.05.

Cerus (NASDAQ:CERS) last posted its quarterly earnings results on Tuesday, February 26th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.02). The business had revenue of $16.50 million during the quarter, compared to the consensus estimate of $18.74 million. Cerus had a negative return on equity of 65.35% and a negative net margin of 84.15%. The business’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.10) earnings per share. Sell-side analysts predict that Cerus Co. will post -0.42 EPS for the current year.

A number of research analysts have recently commented on CERS shares. BidaskClub upgraded shares of Cerus from a “sell” rating to a “hold” rating in a research report on Friday, March 22nd. ValuEngine upgraded shares of Cerus from a “buy” rating to a “strong-buy” rating in a research report on Monday, February 4th. Finally, Zacks Investment Research lowered shares of Cerus from a “hold” rating to a “sell” rating in a research report on Tuesday, January 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $8.50.

TRADEMARK VIOLATION NOTICE: This report was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.baseballdailydigest.com/news/2019/04/27/new-york-state-common-retirement-fund-sells-18800-shares-of-cerus-co-cers.html.

About Cerus

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Further Reading: Compound Interest and Why It Matters When Investing

Institutional Ownership by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.